TALS - Earnings announcements

Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker predictive of achieving tolerance Conference call scheduled for today at 8:00 a.m. ET BOSTON and LOUISVILLE, Ky., June 30, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood diso

Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term follow up of Phase 2 patients, all patients originally weaned off IS have continued to remain off IS without rejecting their donated kidney Update on FREEDOM-1 study originally planned for June 8 now rescheduled to June 30 BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the sta

BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients. The conference call will be held on June 8, 2022 at 8:00 a.m. ET. To access the conference call, the dial-in numbers are 1-855-605-1739 for domestic callers and 1-914-9

Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipientsPoster with additional data from Phase 2 study follow-up to be presented at ASNTalaris to host investor conference call on November 4, 2021, to discuss data BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021. In a poster being presented at the ASN meeting, Talaris will share data from continued long-term follow-up of patients treated in